Sichuan Kelun Pharmaceutical Co., Ltd. announces its subsidiary, Kelun-Biotech, has received approval from China's NMPA for the IND application of its novel dual-payload ADC drug SKB565. This drug, targeting advanced solid tumors, represents Kelun-Biotech's first ADC to enter clinical trials. The approval signifies a significant step in the company's ADC+IO strategy.
Summary generated by AI · Always verify with source document
Stock Code: 002422
Stock Abbreviation: Kelun Pharmaceutical
Announcement Number: 2026-058
Sichuan Kelun Pharmaceutical Co., Ltd.
Announcement on Subsidiary's New Drug SKB565 Clinical Trial Application Approved by National Medical Products Administration
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.